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During the history of antipsychotic medications, the
dopamine D2 receptor has been the crucial main target of
drug action. Typical antipsychotics, which dominated the
first 25 years of antipsychotic treatment as well as atypical
antipsychotics, medications of the last three decades, all
retained dopamine D2 receptor antagonism as the basic
mode of action. Whether the superior side-effect profile
(fewer extrapyramidal symptoms) of atypical antipsy-
chotic agents is due to their serotonin 5-HT2A receptor
antagonist activity or to their looser binding to the
dopamine D2 receptor is still a matter of debate. Brain
imaging studies demonstrating a strong relationship
between dopamine D2 receptor occupancy and clinical
effects and side effects of antipsychotics gave fundamental
support for a central role of dopamine D2 receptors in the
pathology and therapy of schizophrenia. The clinical fail-
ure of alternative approaches lacking the D2 component,
such as selective serotonin 5-HT2A  and dopamine D4
receptor antagonists further pointed at the indispensable
role of D2 antagonism. The recently developed atypical
antipsychotic agent, aripiprazole, while preserving the
predominant D2 action, introduced a new pharmacologi-
cal approach: dopamine D2 receptor partial agonism. An
appropriate degree of partial agonism presumably results
in effective blockade of overstimulated dopamine D2
receptors and improvement in psychotic symptoms, while
it prevents the induction of extrapyramidal side effects or
secondary negative symptoms by avoiding complete
silencing of dopaminergic transmission. In recent years,
the glutamatergic hypothesis for the pathology of the dis-
ease has gradually gained acceptance. Beside theoretical
considerations, this concept was initially fuelled by some
successful trials with the glutamate NMDA receptor co-
agonists glycine, D-cycloserine and D-serine on the nega-
tive symptoms of the disease. However, their efficacy was
modest and these compounds were still applied as
adjunct therapy to the standard D2 dopaminergic antipsy-
chotics. The most recent and, perhaps, most promising
''challenge'' to the D2 centred therapy of schizophrenia
has been the successful proof of concept trial with the
selective metabotropic glutamatergic receptor mGlu2/
mGlu3 agonist prodrug compound, LY2140023. How-
ever, confirmation of the clinical efficacy of the com-
pound is still awaited, and it has been raised that the
compound may eventually affect - though indirectly -
dopaminergic mechanisms. It seems, despite several bur-
ial attempts and attractive alternative hypotheses and tre-
mendous drug development efforts, the therapy of
schizophrenia cannot - so far - detach itself from the
dopaminergic system.
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